Taming the Opioid Epidemic: The National Institutes of Health HEAL Initiative

Ordookhanian, Christ; Kaloostian, Paul E.; Mattei, Tobias A.

doi:10.1016/j.wneu.2018.09.205

Cited by 3 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional logistical barriers such as long wait times and lack of coverage for treatment exacerbate the situation [ 18 ]. Nevertheless, resource allocation is beginning to catch up, with government sectors diverting more money towards the opioid crisis [ 19 ]. More germane to this study, the NIH’s recent Helping to End Addiction Long-term ® (HEAL) project has committed US$ 500 million in research and collaborative efforts to combat the crisis [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, resource allocation is beginning to catch up, with government sectors diverting more money towards the opioid crisis [ 19 ]. More germane to this study, the NIH’s recent Helping to End Addiction Long-term ® (HEAL) project has committed US$ 500 million in research and collaborative efforts to combat the crisis [ 19 ]. It will be important in the future to relate research efforts and other programmes jointly to changes in DALYs.…”

Section: Discussionmentioning

confidence: 99%

“…The lack of a significant association between research allocation and change in DALYs could also reflect lower allocations: it could be argued that levels of funding proportionate to those for HIV/AIDS would lead to improvements for these disorders too. Unlike diseases such as HIV/AIDS, psychiatric disorders may also be less tractable to improvement [ 19 ]; for example, factors such as societal and individual-level stigma are difficult to change [ 21 , 22 ]. Furthermore, low treatment-seeking behaviour and undertreatment still remain a large problem even in the United States, and the quality of mental health services for those receiving treatment could also be improved regardless of research fund allocations [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Exploring static and dynamic relationships between burden of disease and research funding in the United States

Nimgaonkar

Mughal

Heimer

et al. 2022

Health Res Policy Sys

View full text Add to dashboard Cite

Background The relationship between burden of disease and research funding has been examined cross-sectionally, but temporal patterns have not been investigated. It is logical to assume that temporal improvements in disability-adjusted life-years (DALYs) reflect benefits from research funding; such assumptions are tempered by an unknown lag time for emergence of benefits from research. Methods We studied National Institutes of Health (NIH) research fund allocations and United States DALY estimates for overlapping disease categories (matched disease categories, MDC, N = 38). Using a general linear model, we separately analysed DALYs for MDCs in 2017 in relation to NIH research allocations in 2017 and 2007. We also examined how changes in DALYs were related to cumulative NIH research funding (2006–2017). After regressing DALY change on summed funding, we obtained model residuals as estimates of the discrepancy for each MDC between observed and expected change in burden, given funding. Results In 2017, there was a positive association between NIH research fund allocations and DALYs for the same year (F1,36 = 16.087, p = 0.0002921; slope = 0.35020; model R2 = 0.3088), suggesting proportionate allocation. There was a positive association between 2017 DALYs and 2007 NIH research allocation, implying a beneficial impact of research (F1,36 = 15.754, p = 0.0003; slope = 0.8845; model R2 = 0.3044). In contrast, there was a nonsignificant association between summed NIH funding and percent change in DALYs over 2006–2017 (F1,36 = 0.199; p = 0.65; beta coefficient = −1.144). When MDCs were ordered based on residuals, HIV/AIDS ranked first. Mental, neurologic or substance abuse (MNS) disorders comprised most residuals in the lower half. Conclusions NIH fund allocation is proportional to DALYs for MDCs. Temporal changes in DALYs vary by MDCs, but they are not significantly related to cumulative research outlays. Further analysis of temporal changes in DALYs could help to inform research outlays for MDCs and to study the impact of research.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exploring static and dynamic relationships between burden of disease and research funding in the United States

Nimgaonkar

Mughal

Heimer

et al. 2022

Health Res Policy Sys

View full text Add to dashboard Cite

show abstract

“…The Centers for Disease Control and Prevention (CDC) estimated the total economic burden of prescription opioid misuse in the United States to be 78.5 billion dollars a year [17]. In April 2018, to address this national crisis, the US Department of Health and Human Services launched an initiative with the National Institute of Health called “Helping to End Addiction Long-term (HEAL)”, to improve the treatment of opioid misuse and for exploration of alternative therapies in chronic pain management [18].…”

Section: Introductionmentioning

confidence: 99%

Opioid use disorder is associated with increased mortality and morbidity in patients with gastroparesis

Siddiqui

Bilal

Schorr-Lesnick

et al. 2019

aog

View full text Add to dashboard Cite

Background Opioid use disorder (OUD) epidemic has been declared a nationwide public health emergency by the Department of Health and Human Services. There are limited data regarding OUD in patients with gastroparesis. This study aimed to evaluate the impact of OUD on the outcomes in patients hospitalized with gastroparesis and to delineate the trends associated with OUD and gastroparesis using a nationally representative sample. Methods We used the National (Nationwide) Inpatient Sample database from 2005-2014 to identify patients hospitalized with a primary diagnosis of gastroparesis (ICD 9 Code: 536.3) and a concurrent diagnosis of OUD. We used Pearson chi-square analysis to compare demographics, the independent samples t-test to assess differences in length of stay and cost of care, and multivariate regression analysis to adjust for confounders. Results Between 2005 and 2014, a total of 145,700 patients with a primary diagnosis of gastroparesis were hospitalized in the United States, of whom 4519 (3.1%) had a concurrent diagnosis of OUD. The prevalence of OUD in gastroparesis doubled from 2.1% in 2005 to 4.3% in 2014. After adjusting for confounders, patients with OUD had greater in-hospital mortality (adjusted odds ratio 2.7, 95% confidence interval: 2.1-3.5). Patients with OUD also had significantly longer hospital stays and higher costs. Independent predictors of OUD in patients with gastroparesis were younger age, female sex, alcohol use, depression, and Medicaid insurance. Conclusion OUD in patients with gastroparesis is associated with greater mortality and healthcare resource utilization.

show abstract

Opioid tolerance and opioid-induced hyperalgesia: Is TrkB modulation a potential pharmacological solution?

Lim

Cengiz

2022

Neuropharmacology

View full text Add to dashboard Cite

Taming the Opioid Epidemic: The National Institutes of Health HEAL Initiative

Cited by 3 publications

References 2 publications

Exploring static and dynamic relationships between burden of disease and research funding in the United States

Exploring static and dynamic relationships between burden of disease and research funding in the United States

Opioid use disorder is associated with increased mortality and morbidity in patients with gastroparesis

Opioid tolerance and opioid-induced hyperalgesia: Is TrkB modulation a potential pharmacological solution?

Contact Info

Product

Resources

About